Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 6 art units • 9 examiners • 0 of 9 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Bioventures LLC is currently managing 9 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 9 distinct examiners and 6 distinct art units, reflecting a significant breadth of technical and administrative oversight. ABBOTT, KODYE LEE serves as the busiest examiner for the portfolio, handling 1 pending action.
The presence of 9 pending office actions across 6 distinct art units suggests that the company's Biotechnology & Pharmaceuticals research is multifaceted. Because the workload is spread among 9 distinct examiners, the company must manage a wide variety of examination styles and technical interpretations. This decentralized approach ensures that the portfolio's success is not tied to the decisions of a single examiner.
For a patent practitioner, the involvement of 6 distinct art units indicates that the portfolio covers several specialized biological or pharmaceutical domains. The distribution of 9 pending office actions means that each case requires a tailored response to meet the specific requirements of the assigned examiner. This level of activity in the Biotechnology & Pharmaceuticals sector requires a coordinated strategy to maintain consistency across the active prosecutions.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (11%) |
| §112 only | 4 (44%) |
| Double-patenting + other | 1 (11%) |
| Multi-statute (no §101) | 3 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ABBOTT, KODYE LEE | 1 | 53.1% | +71.4% |
| VOORHEES, CATHERINE M | 1 | 83.5% | +14.0% |
| HASTINGS, ALISON AZAR | 1 | 63.5% | +40.2% |
| COLEMAN, BRENDA LIBBY | 1 | 74.9% | +15.5% |
| MOORE, SUSANNA | 1 | 68.1% | +31.6% |
| LU, CHENG | 1 | 54.1% | +64.1% |
| ROANE, AARON F | 1 | 73.4% | +9.7% |
| RAO, PADMAJA S | 1 | 70.7% | +36.8% |
| NGUYEN, NGHI V | 1 | 53.6% | +50.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18864370 | TRACHEAL COLLAR WITH INTEGRATED SENSORS | VOORHEES, CATHERINE M | — |
| 18277204 | COMPOUNDS FOR PROGRAMMABLE PROTEIN DEGRADATION AND METHODS OF USE FOR THE TREATMENT OF DISEASE | COLEMAN, BRENDA LIBBY | — |
| 18262682 | POLY(ADP-RIBOSE) GLYCOHYDROLASE (PARG) INHIBITORS AGAINST COVID MACRODOMAIN AND METHODS OF USING THE SAME | MOORE, SUSANNA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17799638 | NOVEL TDZD ANALOGS AS AGENTS THAT DELAY, PREVENT, OR REVERSE AGE-ASSOCIATED DISEASES AND AS ANTI-CANCER AND ANTILEUKEMIC AGENTS | RAO, PADMAJA S | 12d |
| 17769663 | BIOLOGICALLY SYNTHESIZED HYDROXYAPATITE FOR BONE REGENERATION AND TISSUE ENGINEERING | NGUYEN, NGHI V | 28d |
| 18867764 | USE OF ENGINEERED JURONA VIRUS (JURV) AS AN ONCOLYTIC VIRUS PLATFORM FOR HUMAN CANCERS | ABBOTT, KODYE LEE | — |
| 18864370 | TRACHEAL COLLAR WITH INTEGRATED SENSORS | VOORHEES, CATHERINE M | — |
| 18719745 | SMALL MOLECULE DRUGS THAT REDUCE PROTEIN AGGREGATION | HASTINGS, ALISON AZAR | — |
| 18277204 | COMPOUNDS FOR PROGRAMMABLE PROTEIN DEGRADATION AND METHODS OF USE FOR THE TREATMENT OF DISEASE | COLEMAN, BRENDA LIBBY | — |
| 18262682 | POLY(ADP-RIBOSE) GLYCOHYDROLASE (PARG) INHIBITORS AGAINST COVID MACRODOMAIN AND METHODS OF USING THE SAME | MOORE, SUSANNA | — |
| 18144142 | T CELLS AGAINST HUMAN PAPILLOMAVIRUS | LU, CHENG | — |
| Art Unit | Apps |
|---|---|
| 1624 | 2 |
| 1634 | 1 |
| 1642 | 1 |
| 3792 | 1 |
| 1627 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18867764 | USE OF ENGINEERED JURONA VIRUS (JURV) AS AN ONCOLYTIC VIRUS PLATFORM FOR HUMAN CANCERS | ABBOTT, KODYE LEE | 1634 | §112 | Final Rejection | — | Pending | Nov 20, 2024 |
| 18864370 | TRACHEAL COLLAR WITH INTEGRATED SENSORS | VOORHEES, CATHERINE M | — | §102§103 | Non-Final OA | — | Pending | Nov 08, 2024 |
| 18719745 | SMALL MOLECULE DRUGS THAT REDUCE PROTEIN AGGREGATION | HASTINGS, ALISON AZAR | — | §102DP | Non-Final OA | — | Pending | Jun 13, 2024 |
| 18277204 | COMPOUNDS FOR PROGRAMMABLE PROTEIN DEGRADATION AND METHODS OF USE FOR THE TREATMENT OF DISEASE | COLEMAN, BRENDA LIBBY | 1624 | §102§112 | Non-Final OA | — | Pending | Aug 14, 2023 |
| 18262682 | POLY(ADP-RIBOSE) GLYCOHYDROLASE (PARG) INHIBITORS AGAINST COVID MACRODOMAIN AND METHODS OF USING THE SAME | MOORE, SUSANNA | 1624 | §102§112 | Non-Final OA | — | Pending | Jul 24, 2023 |
| 18144142 | T CELLS AGAINST HUMAN PAPILLOMAVIRUS | LU, CHENG | 1642 | §112 | Final Rejection | — | Pending | May 05, 2023 |
| 17919454 | PHOTOSENSITIZER CONJUGATED GOLD NANOPARTICLES FOR RADIOTHERAPY ENHANCEMENT | ROANE, AARON F | 3792 | §103 | Final Rejection | — | Pending | Oct 17, 2022 |
| 17799638 | NOVEL TDZD ANALOGS AS AGENTS THAT DELAY, PREVENT, OR REVERSE AGE-ASSOCIATED DISEASES AND AS ANTI-CANCER AND ANTILEUKEMIC AGENTS | RAO, PADMAJA S | 1627 | §112 | Final Rejection | 12d | Pending | Aug 12, 2022 |
| 17769663 | BIOLOGICALLY SYNTHESIZED HYDROXYAPATITE FOR BONE REGENERATION AND TISSUE ENGINEERING | NGUYEN, NGHI V | 1653 | §112 | Final Rejection | 28d | Pending | Apr 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial